The MEDIOS-AI, designed by Bangalore-based Remidio Innovative Solutions, will implement sensitive and scalable screening models for Diabetic Retinopathy.... Sep 27
Post-hoc analysis of the EMPA-REG OUTCOME® trial in adults with type 2 diabetes and established cardiovascular disease examined the cardiovascular benefits of empagliflozin ... Sep 20
-Advertisements-